Human PD-1 - Pembrolizumab & Nivolumab Biosimilar Antibodies
Anti-human Programmed Cell Death 1 (PD-1) recombinant monoclonal antibodies
These anti-human PD-1 biosimilar antibodies comprise the variable region of either Pembrolizumab or Nivolumab and their original constant region or a different one with distinct effector functions (ADCC and ADCP).
Pembrolizumab & Nivolumab Biosimilar Isotypes
Both Pembrolizumab and Nivolumab contain a human IgG4 (S228P) constant region and display low effector functions; the other biosimilars feature an IgG1 or IgG1fut (non-fucosylated) constant region that exhibits high effector functions. These non-therapeutic antibodies can be used for the comparative study of the complex interactions induced by their Fc domains.
Key features
- Each lot is functionally tested and validated
- Choice of different anti-hPD-1 clones
- Choice of different isotypes for high/low effector functions
- The complete sequence of the antibody constructs has been verified
- Absence of endotoxins determined by the EndotoxDetect assay
Pembrolizumab & Nivolumab background
Pembrolizumab, a humanized IgG4 (S228P) monoclonal antibody (mAb), and Nivolumab, a fully human IgG4 (S228P), both target the programmed cell death 1 (PD-1) receptor found on activated T cells, B cells, and myeloid cells. Under normal physiological conditions, PD-1 negatively regulates T cell activation thereby preventing autoimmunity. Under pathological conditions, cancer cells produce PD-L1 (programmed cell death 1 ligand 1), the agonist that binds and activates PD-1. Activated PD-1 enables cancer cells to evade the immune system. Pembrolizumab and Nivolumab bind and inhibit the PD-1 receptor, thereby resulting in the activation of T cells. Both antibodies contain an engineered hinge region mutation (S228P) designed to prevent the exchange of IgG4 molecules. Both are approved by the FDA and the EU for the treatment of a variety of cancer types, including non-small cell lung cancer, melanoma, and gastric cancer.
View our product flyer on Clinically relevant monoclonal antibodies
InvivoGen’s products are for research use only, and not for clinical or veterinary use.